Abstract
The exquisite sensitivity of haematological malignancies to targeted radiation alongside the impressive results achieved by the pioneers in this field suggests that radioimmunotherapy is likely to be a productive area for future clinical research. Recent experimental work has demonstrated that the combination of targeted radiation and antibody effector mechanisms are critical to long-term clearance of tumour. This review provides the background of clinical and biological insights into the mechanisms of action of radioimmunotherapy. © 2008 The Authors.
Original language | English |
---|---|
Pages (from-to) | 987-998 |
Number of pages | 11 |
Journal | Journal of Pharmacy and Pharmacology |
Volume | 60 |
Issue number | 8 |
DOIs | |
Publication status | Published - Aug 2008 |
Keywords
- Algorithms
- Animals
- therapeutic use: Antibodies, Monoclonal
- Decision Trees
- Dose-Response Relationship, Drug
- Humans
- immunology: Lymphoma
- methods: Radioimmunotherapy
- therapeutic use: Radiopharmaceuticals
- Radiotherapy Dosage
- Treatment Outcome